Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III crossover study of preservative-free generic latanoprost vs Xalatan in ocular hypertension and open-angle glaucoma
2018-001727-39Phase 3Completed
- Sponsor
- Polpharma
- Start
- Aug 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of latanoprost in ocular hypertension and open-angle glaucoma (OAG) (2 arms), sponsored by Polpharma. Started Aug 2018; status: completed.
02
Drugs
latanoprost
03
Conditions
ocular hypertensionopen-angle glaucoma (OAG)
Beyond the preview
Go deeper on 2018-001727-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001727-39.